A
Apolipoprotein B
Lipids & LipoproteinsLab test / biomarkerriskmodifiablegenetic-causal
74
evidence score
Also known as: Apolipoprotein B (elevated), Apolipoprotein B (low), Apolipoprotein B levels, apo b, apob, high plasma levels of apolipoprotein B, low levels
PREVENT status
Not a PREVENT input variable.
Causal support
genetic causal candidate
Score components
lit volume: 21.1meta-analyses: 15.8trials: 7genetic: 20MR bonus:
Associated genes
APOB
References (127)
5 meta-analyses / systematic reviews- METAIncreased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression. — Neuroscience and biobehavioral reviews 2025 · PMID 39793682
- METAImmunotherapy and vaccine-based approaches for atherosclerosis prevention: a systematic review study. — BMC cardiovascular disorders 2025 · PMID 40114074
- METAAssociation of remnant cholesterol with risk of cardiovascular disease events, stroke, and mortality: A systemic review and meta-analysis. — Atherosclerosis 2023 · PMID 36966562
- METAPortfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. — Progress in cardiovascular diseases 2018 · PMID 29807048
- METAAssociation of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. — JAMA 2012 · PMID 22453571
- Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial. — JAMA 2025 · PMID 39556768
- Apolipoprotein B-containing lipoproteins in atherogenesis. — Nature reviews. Cardiology 2025 · PMID 39743565
- Cardiovascular Risk Factor and Atherosclerosis in Rheumatoid Arthritis (RA). — Current cardiology reports 2025 · PMID 39831939
- Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis. — Clinical rheumatology 2025 · PMID 39962010
- Polygenic Scores of Cardiometabolic Risk Factors in American Indian Adults. — JAMA network open 2025 · PMID 40072435
- Discordance analyses comparing LDL cholesterol, Non-HDL cholesterol, and apolipoprotein B for cardiovascular risk estimation. — Atherosclerosis 2025 · PMID 40073776
- ApoB-containing lipoproteins: count, type, size, and risk of coronary artery disease. — European heart journal 2025 · PMID 40289348
- Concordance-discordance between apolipoprotein B and lipid biomarkers in predicting 20-year atherosclerotic cardiovascular disease risk: The ATTICA study (2002-2022). — European journal of clinical investigation 2025 · PMID 40386959
- Cardiometabolic determinants of aortic and carotid intima-media thickness in adolescence. — Atherosclerosis 2025 · PMID 40413966
- Causal association of modifiable factors with cardiometabolic multimorbidity: an exposome-wide Mendelian randomization investigation. — Cardiovascular diabetology 2025 · PMID 40481456
- Beyond cholesterol: linking the conformation of apolipoprotein B to atherogenesis. — Current opinion in lipidology 2025 · PMID 40549487
- Cumulative exposure to atherogenic lipoprotein particles in young adults and subsequent incident atherosclerotic cardiovascular disease. — European heart journal 2025 · PMID 40613415
- Low apolipoprotein B and LDL-cholesterol are associated with the risk of cardiovascular and all-cause mortality: a prospective cohort. — Annals of medicine 2025 · PMID 40642933
- ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk. — Journal of clinical lipidology 2025 · PMID 40681368
- Estimated Small, Dense LDL Cholesterol and Atherosclerotic Cardiovascular Risk in the UK Biobank. — Arteriosclerosis, thrombosis, and vascular biology 2025 · PMID 40808652
- Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis. — Journal of the American College of Cardiology 2025 · PMID 40888776
- The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. — European heart journal 2025 · PMID 40911366
- Atherogenic responsibility of lipoprotein (a) and other apolipoprotein B-containing lipoproteins in acute coronary syndrome. — Atherosclerosis 2025 · PMID 41092520
- The designer cytokine IC7Fc attenuates atherosclerosis development by targeting hyperlipidemia in mice. — Science advances 2025 · PMID 41134879
- Dietary, macronutrient, micronutrient, and nutrigenetic factors impacting cardiovascular risk markers apolipoprotein B and apolipoprotein A1: a narrative review. — Nutrition reviews 2024 · PMID 37615981
- Dynamic metabolism of endothelial triglycerides protects against atherosclerosis in mice. — The Journal of clinical investigation 2024 · PMID 38175710
- Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis. — Journal of the American College of Cardiology 2024 · PMID 38233012
- Associations of 50 modifiable risk factors with atrial fibrillation using Mendelian randomization analysis. — European journal of clinical investigation 2024 · PMID 38438337
- Remnant Cholesterol, Not LDL Cholesterol, Explains Peripheral Artery Disease Risk Conferred by apoB: A Cohort Study. — Arteriosclerosis, thrombosis, and vascular biology 2024 · PMID 38511326
- Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. — The New England journal of medicine 2024 · PMID 38587249
- Exploring Genetic Associations of 3 Types of Risk Factors With Ischemic Stroke: An Integrated Bioinformatics Study. — Stroke 2024 · PMID 38591222
- Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. — European heart journal 2024 · PMID 38700053
- Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. — American heart journal 2024 · PMID 38705341
- Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. — Journal of the American College of Cardiology 2024 · PMID 38839200
- Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice. — Circulation 2024 · PMID 38950110
- Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. — Journal of clinical lipidology 2024 · PMID 39256087
- Quantifying Triglyceride-Rich Lipoprotein Atherogenicity, Associations With Inflammation, and Implications for Risk Assessment Using Non-HDL Cholesterol. — Journal of the American College of Cardiology 2024 · PMID 39322327
- Lipoprotein(a) and risk-weighted apolipoprotein B: a novel metric for atherogenic risk. — Lipids in health and disease 2024 · PMID 39334349
- Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes. — Current diabetes reports 2024 · PMID 39356419
- Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk. — American heart journal 2024 · PMID 39643097
- High-density lipoprotein revisited: biological functions and clinical relevance. — European heart journal 2023 · PMID 36337032
- The Association between Apolipoprotein B, Cardiovascular Risk Factors and Subclinical Atherosclerosis-Findings from the SEPHAR National Registry on Hypertension in Romania. — International journal of molecular sciences 2023 · PMID 36769130
- Remnant cholesterol, vascular risk, and prevention of atherosclerosis. — Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis 2023 · PMID 36889989
- Cholesterol Remnants, Triglyceride-Rich Lipoproteins and Cardiovascular Risk. — International journal of molecular sciences 2023 · PMID 36901696
- Genetic and clinical factors underlying a self-reported family history of heart disease. — European journal of preventive cardiology 2023 · PMID 37011137
- Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes. — Journal of the American College of Cardiology 2023 · PMID 37137588
- Apolipoprotein Particle and Cardiovascular Risk Prediction (from a Prospective Cohort Study). — The American journal of cardiology 2023 · PMID 37352662
- Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study. — European heart journal 2023 · PMID 37358553
- Apolipoprotein B compared with low-density lipoprotein cholesterol in the atherosclerotic cardiovascular diseases risk assessment. — Pharmacological research 2023 · PMID 37517561
- Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes. — Science (New York, N.Y.) 2023 · PMID 37651538
- Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives. — International journal of environmental research and public health 2023 · PMID 37754581
- Triglyceride-rich lipoprotein cholesterol and cardiovascular risk. — Current opinion in lipidology 2023 · PMID 37773930
- Oxidized phospholipids in cardiovascular disease. — Nature reviews. Cardiology 2023 · PMID 37848630
- Genetic backgrounds and diagnosis of familial hypercholesterolemia. — Clinical genetics 2023 · PMID 37849044
- Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B for cardiovascular care. — Current opinion in cardiology 2023 · PMID 37934698
- Apolipoprotein B and interleukin 1 receptor antagonist: reversing the risk of coronary heart disease. — Frontiers in endocrinology 2023 · PMID 37941911
- Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial. — American heart journal 2023 · PMID 38160917
- Microbiome and Cardiovascular Disease. — Handbook of experimental pharmacology 2022 · PMID 32185503
- Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. — JAMA cardiology 2022 · PMID 34773460
- Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia. — Current opinion in lipidology 2022 · PMID 34907966
- Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. — European heart journal 2022 · PMID 35025993
- New targets for treating hypertriglyceridemia. — Current opinion in endocrinology, diabetes, and obesity 2022 · PMID 35045528
- Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review. — Journal of the American College of Cardiology 2022 · PMID 35210038
- Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. — Circulation 2022 · PMID 35770629
- Genetic and molecular architecture of familial hypercholesterolemia. — Journal of internal medicine 2022 · PMID 36196022
- Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. — Journal of the American Heart Association 2022 · PMID 36216435
- Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk — New England Journal of Medicine 2022 · PMID 36342113
- Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. — JAMA cardiology 2021 · PMID 33471027
- Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. — Journal of the American College of Cardiology 2021 · PMID 33736827
- New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4. — Journal of the American College of Cardiology 2021 · PMID 33766264
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. — The Canadian journal of cardiology 2021 · PMID 33781847
- Genetics of hypertriglyceridemia and atherosclerosis. — Current opinion in cardiology 2021 · PMID 33818545
- Update on apolipoprotein B. — Current opinion in lipidology 2021 · PMID 33870931
- The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk. — Current opinion in lipidology 2021 · PMID 33900275
- APOE gene variants in primary dyslipidemia. — Atherosclerosis 2021 · PMID 34058468
- Prioritizing the Role of Major Lipoproteins and Subfractions as Risk Factors for Peripheral Artery Disease — Circulation 2021 · PMID 34139859
- Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. — European heart journal 2021 · PMID 34293083
- Apolipoproteins in vascular biology and atherosclerotic disease. — Nature reviews. Cardiology 2021 · PMID 34625741
- Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. — Arteriosclerosis, thrombosis, and vascular biology 2021 · PMID 34647487
- Anti-inflammatory therapy in atherosclerosis. — Frontiers in bioscience (Landmark edition) 2020 · PMID 31585888
- Association of Monogenic vs Polygenic Hypercholesterolemia With Risk of Atherosclerotic Cardiovascular Disease — JAMA Cardiology 2020 · PMID 32049305
- High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. — Metabolic syndrome and related disorders 2020 · PMID 32119801
- Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease — Diabetes 2020 · PMID 32198194
- Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis. — International journal of molecular sciences 2020 · PMID 32218354
- Lipoprotein(a) and Cardiovascular Diseases ― Revisited ― — Circulation Journal 2020 · PMID 32336721
- Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease — Journal of Atherosclerosis and Thrombosis 2019 · PMID 31061262
- Antisense Oligonucleotides Targeting Lipoprotein(a). — Current atherosclerosis reports 2019 · PMID 31111240
- Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease — Circulation 2019 · PMID 31216866
- Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. — JAMA cardiology 2019 · PMID 31642874
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease — JAMA 2019 · PMID 31714986
- Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. — Clinical journal of the American Society of Nephrology : CJASN 2019 · PMID 31831577
- Incretins and Lipid Metabolism. — Current medicinal chemistry 2018 · PMID 28413961
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome — New England Journal of Medicine 2018 · PMID 30403574
- Mipomersen and its use in familial hypercholesterolemia. — Expert opinion on pharmacotherapy 2018 · PMID 30526168
- Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease — F1000Research 2017 · PMID 28299190
- Triglyceride Rich Lipoprotein -LPL-VLDL Receptor and Lp(a)-VLDL Receptor Pathways for Macrophage Foam Cell Formation. — Journal of atherosclerosis and thrombosis 2017 · PMID 28428482
- Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis — Circulation Research 2016 · PMID 26892959
- Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. — European heart journal 2016 · PMID 27122601
- Apolipoprotein B and apolipopotein A-I in vascular risk prediction - a review. — Current pharmaceutical design 2014 · PMID 24953398
- LOX-1 in atherosclerotic disease. — Clinica chimica acta; international journal of clinical chemistry 2014 · PMID 25463747
Clinical trials (4)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT05179954 | Apolipoprotein C3-loading of Apolipoprotein B100 Lipoproteins and Cardiovascular Disease in Patients With Type 1 Diabetes | RECRUITING | INTERVENTIONAL | Metabolic testing |
| NCT04656028 | Impact of Genetic Testing and Motivational Counseling on the Adherence to Healthy Lifestyle and Hypolipidemic Therapy and Efficiency of Cascade Screening in Patients With Familial Hypercholesterolemia (GENMOTIV-FH) | ACTIVE NOT RECRUITING | INTERVENTIONAL | Genetic Testing, Motivational Counseling, Lipid analysis |
| NCT01334229 | A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Sitagliptin on the Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and Apolipoprotein B100 in Patients With Type 2 Diabetes | COMPLETED | INTERVENTIONAL | Sitagliptin, Placebo |
| NCT02770872 | The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk | COMPLETED | OBSERVATIONAL | Observation of SAA on apoB containing lipoproteins |
Genetic associations (198)
showing top 80 by significance| Variant | Gene(s) | Trait | p | OR/β | Study |
|---|---|---|---|---|---|
| APOB, TDRD15 | 1e-971 | — | GCST90239655 | ||
| APOB, TDRD15 | 1e-796 | — | GCST90239673 | ||
| APOB, TDRD15 | 1e-693 | 0.0962978 unit increase | GCST90239658 | ||
| APOB, TDRD15 | 1e-670 | — | GCST90239667 | ||
| APOB | 1e-622 | 0.13 % decrease | GCST90501130 | ||
| APOB, TDRD15 | 1e-544 | 0.0852062 unit increase | GCST90239676 | ||
| APOB | 1e-506 | 0.12 mmol/L decrease | GCST90501268 | ||
| APOB | 1e-477 | 0.11 % increase | GCST90501124 | ||
| APOB, TDRD15 | 1e-472 | 0.0944404 unit increase | GCST90239670 | ||
| APOB | 1e-442 | 0.1 % increase | GCST90501151 | ||
| APOB | 1e-420 | 0.1 % increase | GCST90501122 | ||
| APOB | 1e-418 | 0.525 unit increase | GCST90247157 | ||
| APOB | 1e-401 | 0.11 mmol/L decrease | GCST90501265 | ||
| APOB | 1e-398 | — | GCST90239661 | ||
| APOB | 1e-389 | 0.1 ratio decrease | GCST90501273 | ||
| APOB | 1e-389 | 0.1 % decrease | GCST90501245 | ||
| APOB | 1e-388 | 0.11 % decrease | GCST90501197 | ||
| APOB | 1e-383 | 0.1 mmol/L decrease | GCST90501328 | ||
| APOB | 1e-382 | 0.1 % increase | GCST90501199 | ||
| APOB, TDRD15 | 1e-374 | 0.0873 unit increase | GCST90662892 | ||
| APOB | 1e-364 | 0.1 mmol/L decrease | GCST90501264 | ||
| APOB | 1e-359 | 0.1 % decrease | GCST90501149 | ||
| APOB | 1e-353 | 0.1 mmol/L decrease | GCST90501160 | ||
| APOB, TDRD15 | 1e-343 | 0.0794 unit increase | GCST90662895 | ||
| APOB | 1e-341 | 0.1 mmol/L decrease | GCST90501158 | ||
| APOB | 1e-339 | 0.1 mmol/L decrease | GCST90501216 | ||
| APOB, LINC02850 | 1e-335 | 0.0839859 unit decrease | GCST010243 | ||
| APOB | 1e-326 | 0.09 mmol/L decrease | GCST90501166 | ||
| APOB | 1e-323 | 0.09 % decrease | GCST90501193 | ||
| APOB | 1e-316 | 0.1 % increase | GCST90501203 | ||
| APOB | 1e-316 | 0.2335 unit decrease | GCST90019496 | ||
| APOB | 1e-315 | 0.09 mmol/L decrease | GCST90501162 | ||
| APOB | 1e-313 | 0.09 mmol/L decrease | GCST90501332 | ||
| APOB, TDRD15 | 1e-312 | 0.0831886 unit decrease | GCST010245 | ||
| APOB | 1e-308 | 0.09 mmol/L decrease | GCST90501330 | ||
| APOB | 1e-308 | 0.09 mmol/L decrease | GCST90501165 | ||
| APOB, LINC02850 | 1e-306 | 0.095 unit decrease | GCST010204 | ||
| APOB | 1e-306 | 0.09 mmol/L decrease | GCST90501164 | ||
| APOB | 1e-295 | 0.09 mmol/L decrease | GCST90501310 | ||
| APOB | 1e-294 | 0.09 mmol/L decrease | GCST90501293 | ||
| APOB | 1e-294 | 0.09 mmol/L decrease | GCST90501334 | ||
| APOB | 1e-293 | — | GCST90239649 | ||
| APOB | 1e-291 | 0.09 mmol/L decrease | GCST90501306 | ||
| APOB | 1e-285 | 0.09 mmol/L decrease | GCST90501289 | ||
| APOB | 1e-284 | 0.08 % increase | GCST90501251 | ||
| APOB | 1e-282 | 0.09 % decrease | GCST90501327 | ||
| APOB | 1e-278 | 0.09 mmol/L decrease | GCST90501282 | ||
| APOB | 1e-277 | 0.08 nm decrease | GCST90501292 | ||
| APOB | 1e-275 | 0.09 mmol/L decrease | GCST90501308 | ||
| APOB | 1e-275 | 0.09 mmol/L decrease | GCST90501314 | ||
| APOB | 1e-274 | 0.09 mmol/L decrease | GCST90501256 | ||
| APOB, TDRD15 | 1e-271 | 0.09 % increase | GCST90501239 | ||
| APOB | 1e-270 | 0.09 mmol/L decrease | GCST90501313 | ||
| APOB | 1e-268 | 1.566 unit increase | GCST90248940 | ||
| APOB | 1e-267 | 0.09 mmol/L decrease | GCST90501291 | ||
| APOB | 1e-262 | 0.08 mmol/L decrease | GCST90501312 | ||
| APOB | 1e-259 | 0.08 mmol/L decrease | GCST90501338 | ||
| APOB | 1e-258 | 0.09 mmol/L decrease | GCST90501212 | ||
| APOB | 1e-257 | 0.08 % decrease | GCST90501305 | ||
| APOB | 1e-256 | 0.08 mmol/L decrease | GCST90501168 | ||
| APOB | 1e-254 | 0.0704109 unit decrease | GCST90239664 | ||
| APOB | 1e-253 | 0.08 % increase | GCST90501183 | ||
| APOB, TDRD15 | 1e-253 | 0.089505926 unit increase | GCST90468066 | ||
| APOB | 1e-252 | 0.08 mmol/L decrease | GCST90501244 | ||
| APOB | 1e-249 | 0.08 % increase | GCST90501321 | ||
| APOB, TDRD15 | 1e-249 | — | GCST008079 | ||
| APOB, LINC02850 | 1e-248 | 0.08 mmol/L increase | GCST90501266 | ||
| APOB | 1e-248 | 0.1181 unit decrease | GCST90475352 | ||
| APOB | 1e-247 | 0.0803 unit increase | GCST90018961 | ||
| APOB | 1e-246 | 0.08 mmol/L decrease | GCST90501288 | ||
| APOB | 1e-245 | 0.07 mmol/L increase | GCST90501260 | ||
| APOB, TDRD15 | 1e-245 | 0.09 mmol/L increase | GCST90501254 | ||
| APOB | 1e-243 | 0.08 mmol/L decrease | GCST90501290 | ||
| APOB | 1e-243 | 0.08 % decrease | GCST90501145 | ||
| APOB | 1e-240 | 0.07 mmol/L increase | GCST90501258 | ||
| APOB, TDRD15 | 1e-236 | 0.1065 unit decrease | GCST90475412 | ||
| APOB, TDRD15 | 1e-236 | 0.09629 unit decrease | GCST90479660 | ||
| APOB, TDRD15 | 1e-231 | 0.08 mmol/L increase | GCST90501156 | ||
| APOB | 1e-230 | 0.08 mmol/L decrease | GCST90501316 | ||
| APOB, TDRD15 | 1e-229 | 0.1008 mg dl-1 increase | GCST006612 |